No Cash Boost For Novartis From Sandoz Spin-Off
Swiss Major Did Not Receive Any Formal Bids For Unit
After a lengthy review, Novartis has confirmed Sandoz will be a publicly traded standalone company listed on the SIX Swiss Exchange, although CEO Vas Narasimhan says he will still consider bids for the division.
